ProCE Banner Activity


Medical Minute 3: Emerging Standardized Microbiota Therapies for Recurrent C. difficile Infection


View this third in a series of 3 modules from the live PCE/AGA Gastroenterology Bootcamp for expert insights on the safety and efficacy of live biotherapeutic products for recurrent C. difficile infection and hear the answers to frequently asked questions.

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurse Practitioners: 0.25 Nursing contact hours, includes 0.25 hour of pharmacotherapy credit

Released: June 16, 2023

Expiration: June 15, 2024

No longer available for credit.



Andrea Banty

Andrea Banty, DNP, FNP

Nurse Practitioner
Cedars-Sinai IBD Center
Los Angeles, California

Colleen Kelly

Colleen Kelly, MD, FACG, AGAF

Associate Professor of Medicine
Division of Gastroenterology
Warren Alpert Medical School of Brown University
Providence, Rhode Island

Provided by

Provided by Partners for Advancing Clinical Education (PACE) in partnership with the American Gastroenterological Association (AGA).

ProCE Banner


Supported by educational grants from Ferring Pharmaceuticals, Inc.

Ferring Pharmaceuticals, Inc.



ProCE Banner

Target Audience

NPs and PAs who practice in gastroenterology.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review the impact of gut dysbiosis on the development of recurrent CDI

  • Detail the safety and efficacy for emerging standardized microbiota therapies for recurrent CDI


Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Andrea Banty, DNP, FNP

Nurse Practitioner
Cedars-Sinai IBD Center
Los Angeles, California

Andrea Banty, DNP, FNP, has no relevant financial relationships to disclose.

Colleen Kelly, MD, FACG, AGAF

Associate Professor of Medicine
Division of Gastroenterology
Warren Alpert Medical School of Brown University
Providence, Rhode Island

Colleen R. Kelly, MD, FACG, AGAF: consultant/advisor/speaker: Sebela Pharmaceuticals.

The planners and content peer reviewers from Partners for Advancing Clinical Education, Practicing Clinicians Exchange, and American Gastroenterological Association do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 16, 2023, through June 15, 2024:

  1.  Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of 65 or better and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

A picture containing logoDescription automatically generated

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


ANCC Credit Designation
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 contact hours, including 0.25 hours of pharmacology credit.

AAPA Credit Designation

AAPAPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credit. Approval is valid until June 15, 2024. PAs should only claim credit commensurate with the extent of their participation.


IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.